Santhera Pharmaceuticals Holdings Ltd.
OOTC:SPHDFCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company News
Santhera Pharmaceuticals Holding AG (SPHDF) Q2 2026 Earnings Call Transcript
Santhera nears cash break-even as AGAMREE gains traction, Edison says
Santhera Pharmaceuticals Holding AG (SPHDF) Q4 2025 Earnings Call Transcript
eBay heads into Q1 earnings with momentum, but macro clouds loom
Santhera reconfirms cash flow breakeven target as AGAMREE revenues near-double
Santhera Pharmaceuticals Full Year Results for the Year Ended 31 December 2025
Santhera wins backing to extend DMD drug AGAMREE to toddlers as young as two
Santhera Pharmaceuticals (OTCMKTS:SPHDF) Trading Up 35.4% – What’s Next?
Santhera Pharmaceuticals: Delivers life-changing treatment to little fanfare. Soon the numbers will support its progress
BlackRock shares jump on Q4 earnings, record $14T assets under management
Santhera lands key approval for DMD treatment in Switzerland
Santhera lands key approval for DMD treatment in Switzerland
Aritzia shares rise as Q3 earnings top expectations
Santhera shares jump after $205 million Asia-Pacific licensing deal
Santhera shares jump after $205 million Asia-Pacific licensing deal
Santhera Pharma strikes $205 million Asia-Pacific deal for Duchenne muscular dystrophy drug
Santhera Pharma strikes $205 million Asia-Pacific deal for Duchenne muscular dystrophy drug
Santhera Pharmaceuticals Holding AG (SPHDF) Q2 2025 Earnings Call Transcript